Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412501 · ClinicalTrials.gov registry record · NA
Medtronic Resolute Onyx 2.0 mm Clinical Study
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
NCT02412501: Completed NA study, sponsored by Medtronic Vascular.
NCT02412501 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 101 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02412501, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm diameter stent.
Primary Outcome
Target Lesion Failure at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (Q wave or non-Q wave) or Target Lesion Revascularization by percutaneous or surgical methods.
Interventions
- DEVICE Resolute Onyx Stent - 2.0 mm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-04-06 |
| Est. Completion | 2019-02-21 |
| Phase | NA |
What the finished NCT02412501 record still lists
NCT02412501 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Resolute Onyx Stent - 2.0 mm is the first listed.
NCT02412501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02412501 about?
NCT02412501 is a clinical study titled "Medtronic Resolute Onyx 2.0 mm Clinical Study". The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries that allows the use of a 2.0 mm diameter stent.
What is the current status of trial NCT02412501?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2015-04-06. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT02412501?
The interventions under investigation include: Resolute Onyx Stent - 2.0 mm (DEVICE).
Who is sponsoring clinical trial NCT02412501?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02412501's enrollment target sits among peer trials
101 840th of 2000 higher than 1,161 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI